 Genetic Therapy
"Genetic Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.
| Descriptor ID |
D015316
|
| MeSH Number(s) |
E02.095.301 E05.393.420.301
|
| Concept/Terms |
Genetic Therapy- Genetic Therapy
- Genetic Therapies
- Therapies, Genetic
- Therapy, Genetic
- Therapy, DNA
- DNA Therapy
Genetic Therapy, Somatic- Genetic Therapy, Somatic
- Genetic Therapies, Somatic
- Somatic Genetic Therapies
- Somatic Genetic Therapy
- Therapies, Somatic Genetic
- Therapy, Somatic Genetic
Genetic Therapy, Gametic- Genetic Therapy, Gametic
- Gametic Genetic Therapies
- Gametic Genetic Therapy
- Genetic Therapies, Gametic
- Therapies, Gametic Genetic
- Therapy, Gametic Genetic
|
Below are MeSH descriptors whose meaning is more general than "Genetic Therapy".
Below are MeSH descriptors whose meaning is more specific than "Genetic Therapy".
This graph shows the total number of publications written about "Genetic Therapy" by people in this website by year, and whether "Genetic Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 6 | 0 | 6 | | 1996 | 5 | 0 | 5 | | 1997 | 3 | 5 | 8 | | 1998 | 4 | 1 | 5 | | 1999 | 2 | 5 | 7 | | 2000 | 6 | 4 | 10 | | 2001 | 3 | 3 | 6 | | 2002 | 5 | 4 | 9 | | 2003 | 6 | 6 | 12 | | 2004 | 5 | 2 | 7 | | 2005 | 7 | 3 | 10 | | 2006 | 1 | 6 | 7 | | 2007 | 5 | 2 | 7 | | 2008 | 10 | 5 | 15 | | 2009 | 10 | 3 | 13 | | 2010 | 3 | 3 | 6 | | 2011 | 3 | 3 | 6 | | 2012 | 4 | 1 | 5 | | 2013 | 1 | 4 | 5 | | 2014 | 8 | 8 | 16 | | 2015 | 0 | 3 | 3 | | 2016 | 1 | 5 | 6 | | 2017 | 3 | 1 | 4 | | 2018 | 6 | 3 | 9 | | 2019 | 2 | 3 | 5 | | 2020 | 3 | 4 | 7 | | 2021 | 6 | 5 | 11 | | 2022 | 2 | 3 | 5 | | 2023 | 0 | 10 | 10 | | 2024 | 6 | 1 | 7 | | 2025 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Genetic Therapy" by people in Profiles.
-
Cheerie D, Meserve MM, Beijer D, Kaiwar C, Newton L, Taylor Tavares AL, Verran AS, Sherrill E, Leonard S, Sanders SJ, Blake E, Elkhateeb N, Gandhi A, Liang NSY, Morgan JT, Verwillow A, Verheijen J, Giles A, Williams S, Chopra M, Croft L, Dafsari HS, Davidson AE, Friedman J, Gregor A, Haque B, Lechner R, Montgomery KA, Ryten M, Schober E, Siegel G, Sullivan PJ, Whittle EF, Zardetto B, Yu TW, Synofzik M, Aartsma-Rus A, Costain G, Lauffer MC. Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments. Am J Hum Genet. 2025 May 01; 112(5):975-983.
-
Du X, Nakanishi H, Yamada T, Sin Y, Minegishi K, Motohashi N, Aoki Y, Itaka K. Polyplex Nanomicelle-Mediated Pgc-1a4 mRNA Delivery Via Hydrodynamic Limb Vein Injection Enhances Damage Resistance in Duchenne Muscular Dystrophy Mice. Adv Sci (Weinh). 2025 Apr; 12(16):e2409065.
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
-
Cao M, Katial R, Liu Y, Lu X, Gu Q, Chen C, Liu K, Zhu Z, Marshall MR, Yu Y, Wang Z. Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials. Gene Ther. 2025 May; 32(3):223-236.
-
Kim-McManus O, Gleeson JG, Mignon L, Smith Fine A, Yan W, Nolen N, Demarest S, Berry-Kravis E, Finkel R, Leonard S, Finlayson S, Augustine E, Lyon GJ, Schule R, Yu T. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat Commun. 2024 11 12; 15(1):9802.
-
Voit RA, Liao X, Caulier A, Antoszewski M, Cohen B, Armant M, Lu HY, Fleming TJ, Kamal E, Wahlster L, Roche AM, Everett JK, Petrichenko A, Huang MM, Clarke W, Myers KC, Forester C, Perez-Atayde A, Bushman FD, Pellin D, Shimamura A, Williams DA, Sankaran VG. Regulated GATA1 expression as a universal gene therapy for Diamond-Blackfan anemia. Cell Stem Cell. 2025 Jan 02; 32(1):38-52.e6.
-
Rafael Correia Rocha I, Finch MR, Ball JB, Harland ME, Clements M, Green-Fulgham S, Song G, Liu Y, Banov D, Watkins LR. An initial investigation of transcutaneous delivery of plasmid DNA encoding interleukin-10 for the treatment of psoriatic skin conditions. Brain Behav Immun. 2025 Jan; 123:903-913.
-
Eissa H, Cowan MJ, Heimall J. Late effects following hematopoietic cell transplantation for severe combined immunodeficiency: critical factors and therapeutic options. Expert Rev Clin Immunol. 2025 Jan; 21(1):73-82.
-
Jogdeo CM, Siddhanta K, Das A, Ding L, Panja S, Kumari N, Oupick? D. Beyond Lipids: Exploring Advances in Polymeric Gene Delivery in the Lipid Nanoparticles Era. Adv Mater. 2024 Aug; 36(31):e2404608.
-
Itzler R, Buckner TW, Leebeek FWG, Miller J, Recht M, Drelich D, Monahan PE, Pipe SW. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy. Haemophilia. 2024 May; 30(3):709-719.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|